Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
SOX2 mediates metabolic reprogramming of prostate cancer cells.
de Wet L, Williams A, Gillard M, Kregel S, Lamperis S, Gutgesell LC, Vellky JE, Brown R, Conger K, Paner GP, Wang H, Platz EA, De Marzo AM, Mu P, Coloff JL, Szmulewitz RZ, Vander Griend DJ. de Wet L, et al. Oncogene. 2022 Feb;41(8):1190-1202. doi: 10.1038/s41388-021-02157-x. Epub 2022 Jan 24. Oncogene. 2022. PMID: 35067686 Free PMC article.
Selective Glucocorticoid Receptor Modulators (SGRMs) Delay Castrate-Resistant Prostate Cancer Growth.
Kach J, Long TM, Selman P, Tonsing-Carter EY, Bacalao MA, Lastra RR, de Wet L, Comiskey S, Gillard M, VanOpstall C, West DC, Chan WC, Griend DV, Conzen SD, Szmulewitz RZ. Kach J, et al. Among authors: de wet l. Mol Cancer Ther. 2017 Aug;16(8):1680-1692. doi: 10.1158/1535-7163.MCT-16-0923. Epub 2017 Apr 20. Mol Cancer Ther. 2017. PMID: 28428441 Free PMC article.
Self-Assembling Peptide Gels for 3D Prostate Cancer Spheroid Culture.
Hainline KM, Gu F, Handley JF, Tian YF, Wu Y, de Wet L, Vander Griend DJ, Collier JH. Hainline KM, et al. Among authors: de wet l. Macromol Biosci. 2019 Jan;19(1):e1800249. doi: 10.1002/mabi.201800249. Epub 2018 Oct 15. Macromol Biosci. 2019. PMID: 30324687 Free PMC article.
Correction to: SOX2 mediates metabolic reprogramming of prostate cancer cells.
de Wet L, Williams A, Gillard M, Kregel S, Lamperis S, Gutgesell LC, Vellky JE, Brown R, Conger K, Paner GP, Wang H, Platz EA, De Marzo AM, Mu P, Coloff JL, Szmulewitz RZ, Vander Griend DJ. de Wet L, et al. Oncogene. 2022 Feb;41(8):1234. doi: 10.1038/s41388-022-02228-7. Oncogene. 2022. PMID: 35145235 No abstract available.
SOX2 expression in prostate cancer drives resistance to nuclear hormone receptor signaling inhibition through the WEE1/CDK1 signaling axis.
Williams A, Gutgesell L, de Wet L, Selman P, Dey A, Avineni M, Kapoor I, Mendez M, Brown R, Lamperis S, Blajszczak C, Bueter E, Kregel S, Vander Griend DJ, Szmulewitz RZ. Williams A, et al. Among authors: de wet l. Cancer Lett. 2023 Jul 1;565:216209. doi: 10.1016/j.canlet.2023.216209. Epub 2023 May 9. Cancer Lett. 2023. PMID: 37169162 Free article.
Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer.
West DC, Kocherginsky M, Tonsing-Carter EY, Dolcen DN, Hosfield DJ, Lastra RR, Sinnwell JP, Thompson KJ, Bowie KR, Harkless RV, Skor MN, Pierce CF, Styke SC, Kim CR, de Wet L, Greene GL, Boughey JC, Goetz MP, Kalari KR, Wang L, Fleming GF, Györffy B, Conzen SD. West DC, et al. Among authors: de wet l. Clin Cancer Res. 2018 Jul 15;24(14):3433-3446. doi: 10.1158/1078-0432.CCR-17-2793. Epub 2018 Apr 10. Clin Cancer Res. 2018. PMID: 29636357 Free PMC article.
13 results